Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

ABSTRACT: The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Adenocarcinoma,Metastaserende Colorectal Cancer Uden Kras Mutation,Colorectal Neoplasms

PROVIDER: 2064058 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR